RecruitingNCT06400654

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Retrospective and Prospective Observational Study on prognostIc and Predictive Factors in Patients With Extra-pulmonary, adVanced Neuroendocrine cArciNomas and Mixed Adeno-neuroendocrine Carcinomas (NIRVANA)


Sponsor

European Institute of Oncology

Enrollment

100 participants

Start Date

Jul 5, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Extra-pulmonary (EP) poorly differentiated neuroendocrine carcinomas (NECs) represent a rare and aggressive category of neoplasms. Mixed adeno-neuroendocrine carcinomas (MANEC) are a group of rare neoplasms composed by a neuroendocrine (NE) and a non-neuroendocrine (non-NE) component, each representing at least the 30% of the neoplasm. Considering their rarity, low prevalence and poor prognosis a clear clinical, morphological and biomolecular characterization of these neoplasms has been prevented and a clinical approach universally shared is still lacking.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Histological diagnosis of unresectable locally advanced or metastatic NEC or MANEC confirmed by an expert-pathologist
  • EP-primary site (included unknown primary site
  • Age \> 18 years
  • Signed written informed consent
  • Performance status ≤2
  • Available tumor tissue (formalin-fixed paraffin-embedded, FFPE) (preferably within 6 months). If the tumor contained in FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut. Preferably, 25 slides should be provided (minimum of 15 slides). If tumor tissue is not available, patients should be willing to undergone to a new biopsy.

Exclusion Criteria4

  • Diagnosis of well-differentiated NEN (G1, G2, G3)
  • Collision tumors
  • Cytological diagnosis of NEC or MANEC or not availability of tumor tissue for pathological analysis.
  • Concurrent neoplastic disease (e.g. Advanced breast or prostatic cancer in hormonal treatment, hematologic diseases)

Locations(1)

European Institute of Oncology

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06400654


Related Trials